Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Background Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-related adverse events (AEs), indicating the need for improved therapies. Cosibelimab is a high-affinity programmed cell death-ligand 1 (PD-L1)-blocking antibody… Continue reading Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Asymmetric anti-CLL-1xCD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

AI SummaryA study developed a bispecific antibody that targets CLL-1 and CD3 to treat acute myeloid leukemia (AML). The antibody showed strong tumor-killing activity and low cytokine release, making it a promising treatment option for AML patients.Background Acute myeloid leukemia (AML) is a type of leukemia in adults with a high mortality rate and poor… Continue reading Asymmetric anti-CLL-1xCD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release

Contributions of the Sodium Leak Channel NALCN to Pacemaking of Medial Ventral Tegmental Area and Substantia Nigra Dopaminergic Neurons

AI SummaryThe sodium leak channel, NALCN, is found to play a significant role in driving pacemaking in dopaminergic neuron subpopulations in the ventral tegmental area (VTA). However, pacemaking in substantia nigra pars compacta (SNc) neurons is not affected by NALCN. Instead, NALCN regulates the excitability of SNc neurons. These findings have implications for developing targeted… Continue reading Contributions of the Sodium Leak Channel NALCN to Pacemaking of Medial Ventral Tegmental Area and Substantia Nigra Dopaminergic Neurons

Precise genome engineering and protein activity profiling uncover new cancer drug targets

Scripps Research scientists combined two methods to study cysteine residues in proteins previously linked to cancer. Using chemical proteomics (top), they learned which cysteines were accessible to drugs. Using genome editing (bottom), they analyzed the functional consequences of altering each cysteine. Together, they suggest which cysteines may be effective cancer drug targets. Credit: Scripps Research… Continue reading Precise genome engineering and protein activity profiling uncover new cancer drug targets

Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy

AI Summary[18F]DK222-PET is a potential non-invasive tool for monitoring the effects of immunotherapy on tumors. It can detect PD-L1 expression in tumors and quantify therapy-induced changes. It can also differentiate the impact of different therapies on tumors.Background Combination therapies that aim to improve the clinical efficacy to immune checkpoint inhibitors have led to the need… Continue reading Non-invasive PD-L1 quantification using [18F]DK222-PET imaging in cancer immunotherapy

Metal-loving microbes could replace chemical processing of rare earths

AI SummaryScientists have studied the genome of a metal-loving bacteria that can absorb rare earth elements, which could lead to a more environmentally friendly method of processing these elements.Scientists have characterized the genome of a metal-loving bacteria with an affinity for rare earth elements. The research paves the way towards replacing the harsh chemical processing… Continue reading Metal-loving microbes could replace chemical processing of rare earths

Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet

AI SummaryThe study found that the anti-tau monoclonal antibody, semorinemab, showed a significant effect on cognition but did not improve functional or global outcomes in patients with mild-to-moderate Alzheimer’s disease. The results suggest that further exploration of semorinemab or other anti-tau therapies in mild-to-moderate AD may be needed. [Source: Lauriet study on semorinemab in patients… Continue reading Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet